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ABBREVIATIONS
• AIH – Autoimmune Hepatitis
• ANCA – Anti Neutrophil Cytoplasmic antibody
• ASMA – Anti Smooth muscle antibody
• ANA – Anti Nuclear antibody
• AMA – Anti Mitochondrial antibody
• ARA – American Rheumatological association
• ALT – Alanine aminotransferase
• AST – Aspartate aminotransferase
• ALP – Alkaline phosphatase
• ESR – Erythrocyte sedimentation rate
• HBV – Hepatitis B virus
• HCV – Hepatitis C virus
• LFT – Liver function test
• NSAID – Non steroidal anti inflammatory drug
• PT – Prothrombin time
• SLE – systemic Lupus Erythematosus
• RA – Rheumatoid arthritis
• RF – Rheumatoid factor
• LKM – Liver kidney microsome
• SLA/ LP – Soluble liver protein/ Liver pancreas
• PBC – Primary Biliary Cirrhosis
• PSC – Primary Sclerosing Cholangitis
1. INTRODUCTION
Chronic liver disease is an important cause of morbidity and mortality in 
developing  countries (1).Along  with  co-existing  complications  of  portal 
hypertension, liver failure and hepatocellular carcinoma, it puts an enormous 
burden on limited health care resources.
     Common causes of chronic liver disease in developing countries like 
India are Hepatitis B virus and Hepatitis C virus related chronic hepatitis, 
alcohol, drug induced liver disease and metabolic liver disease. Etiology of 
liver  disease  in  women,  especially  younger  women  is  more  likely  to  be 
chronic viral hepatitis and autoimmune disease (2).
    Screening  of  blood  transfusion  donors  and  aggressive  vaccination 
strategies are bound to reduce the prevalence of post hepatitic liver disease. 
Hence it is important to recognize early, other potentially treatable causes 
like autoimmune liver disease.
               
  
2. REVIEW OF LITERATURE
HISTORY
The  first  observation  of  a  link  between  arthritis  and  liver  disease  was 
reported by Still in 1897  (3) and Wishart in 1903  (4). This was followed by 
many attempts at inducing jaundice to ameliorate joint symptoms (5).
Search for the ‘active agent’ in this response induced by jaundice culminated 
in hypotheses that corticosteroid hormone metabolism was deranged in these 
conditions.  This  was  followed  by  first  reports  of  dramatic  response  to 
corticosteroid therapy in rheumatoid arthritis (6).
       Waldenstrom and Kunkel were the first to recognize a syndrome of 
chronic hepatitis in young women with extreme hypergammaglobulinemia. 
Liver  function  abnormalities  in  rheumatoid  arthritis  and other  connective 
tissue disorders were well established and attributed to systemic nature of 
underlying  disease  process  in  a  review  by  Movitt  and  Davies  in 
1953(7).Through  the  next  few decades  many  case  series  of  patients  with 
subclinical  and  clinical  liver  dysfunction  associated  with  autoimmune 
diseases were reported (8,9,10).
            
       In the last 25 years, there has been clarification of terminology from 
lupoid hepatitis to chronic active hepatitis and then to autoimmune hepatitis. 
The explosion of information in fields of genetics and molecular biology has 
given way to new opportunities in understanding the genetic and molecular 
basis for autoimmune liver disease.
DEFINITIONS
• Chronic hepatitis  : A series of liver disorders, of varying cause and 
severity, of chronic inflammatory reactions in the liver as shown by 
liver  function  abnormalities  and  histology,  and  continuing  without 
improvement for at least six months (11).
• Autoimmune  hepatitis  :  Unresolving  inflammation  of  the  liver  of 
unknown cause characterized by presence of interface hepatitis, portal 
plasma  cell  infiltration,  hypergammaglobulinemia  and 
autoantibodies(12).
• Primary  Biliary  Cirrhosis  :  Chronic  progressive  cholestatic  liver 
disease  that  predominately  affects  middle  aged  women  and  is 
characterized  by  chronic  inflammation  and  fibrous  obliteration  of 
intrahepatic bile ductules (11).
• Primary  Sclerosing  Cholangitis:   Chronic  progressive  disorder  of 
unknown  etiology  characterized  by  inflammation,  fibrosis  and 
stricturing of medium to large intrahepatic and extrahepatic bile  ducts 
(11).
Classification of chronic hepatitis
Previous attempts at classifying chronic hepatitis based on localization and 
extent of inflammation, as chronic lobular, persistent and active (13) have now 
been challenged by recent observers. With currently available information, 
classification  of  chronic  hepatitis  based  on  combination  of  clinical, 
serological and histological variables is appropriate. Chronic hepatitis is now 
classifies as:
• Classification by cause:
1. Chronic viral hepatitis: HBV, HCV, HDV, unknown viruses
2. Autoimmune hepatitis: types 1, 2 and 3
3. Drug associated hepatitis
4. Non alcoholic steatohepatitis
5. Wilson’s disease / α 1 antitrypsin deficiency
• Classification by grade:
It is histological assessment of necroinflammatory activity calculated by 
using histological activity index (HAI) given by Knodell  (14) and Ishak 
(15).This index is based on the presence and extent of the following on 
liver biopsy specimens:
1. Periportal necrosis
2. Intralobular necrosis
3. Portal Inflammation
• Classification by stage:
It reflects the level of progression based on degree of fibrosis, ranging 
from mild portal fibrosis (1) to cirrhosis (6).
  LIVER DYSFUNCTION AND RHEUMATOLGY 
A. Primary diseases of liver in which joints are involved:
1. Autoimmune hepatitis
2. Acute viral hepatitis
3. Primary Biliary Cirrhosis
4. Hemochromatosis
5. Wilson’s disease 
B. Primary Rheumatological diseases in which liver is involved:
1. Rheumatoid arthritis/ Sjogren’s syndrome
2. Felty’s syndrome
3. Juvenile idiopathic arthritis (JIA)
4. Adult onset Still’s disease (AOSD)
5. Systemic lupus erythematosus
6. Systemic sclerosis
7. Polymyalgia rheumatica
8. Polyarteritis nodosa 
C. Antirheumatic drug induced liver disease
Primary diseases of liver with Rheumatological 
involvement:
• Primary Biliary Cirrhosis ( PBC)(16-18) 
5 – 9.7 % of patients with PBC have Rheumatoid arthritis. 64 % have 
positive  Rheumatoid  factor  of  which  majority  show  asymptomatic 
joint erosions. Symptomatic arthritis is seen in 10% of patients. The 
sicca complex of dry eyes and mouth is seen in 72%. Scleroderma and 
CREST syndrome are in 17 %, whereas Raynaud’s phenomenon is 
seen in 12% of patients. Flitting arthritis is seen in this disease and is 
due  to  hypercholesterolemia.  Digital  clubbing  and  hypertrophic 
osteoarthropathy have been reported to occur in 35-38% of patients. 
(19) 
• Autoimmune hepatitis
It  is  commonly  associated  with  arthralgia,  stiffness  in  large  joints. 
Rheumatoid factor and ANA are positive in 95% and 84% of patients 
respectively (19). Joint swelling and effusion are less common features.
• Viral hepatitis 
Serum sickness like illness, arthralgia, and rash are seen transiently 
especially in acute viral hepatitis caused by Hepatitis B virus. 
Non erosive arthritis and other manifestations are most likely due to 
an immune complex mediated disorder.
• Hemochromatosis/ Wilson’s
Chronic arthropathy may be the only presenting symptom (20). 75% of 
patients with Wilson’s disease have signs and symptoms related to 
locomotor system in the form of pain and stiffness of knees and spine. 
Hyperextensible  joints  in  the  absence  of  Marfan’s  syndrome  or 
homocysteinuria is another characteristic feature.
Rheumatic diseases with liver involvement
• Rheumatoid arthritis (RA) / Sjogren’s syndrome (21)
Hepatomegaly is seen in 10% of RA and 15% of Sjogren’s but other 
clinical  signs  of  chronic  liver  disease  are  uncommon.  Abnormal 
biochemistry  in  the  form  of  elevated  liver  enzymes,  low  serum 
albumin and elevated globulin are frequently seen. Antimitochondrial 
antibodies are seen in < 1% of RA, 1.5% of Sjogren’s and 6% of 
patients  with  Sicca  syndrome.  Liver  biopsy  shows  non  specific 
hepatitis in 43% and fatty change in 22% of patients.
• Felty’s syndrome (22)
It  is  mentioned separately due to frequent association with  nodular 
regenerative  hyperplasia  of  liver, portal  hypertension  and  its 
complications. Abnormal biochemistry is seen in > 60% of patients 
and  liver  biopsy  shows  Kupffer  cell  prominence  and  sinusoidal 
lymphocytic infiltration.
• Juvenile Idiopathic Arthritis ( JIA) (22)
Hepatic dysfunction is common with systemic onset disease. Elevated 
Bilirubin and liver enzymes are seen in a fifth of all cases with liver 
biopsy  showing  periportal  lyphocytic  infiltration  and  Kupffer  cell 
hyperplasia.
• Adult onset Still’s disease (AOSD) (23)
30%  of  patients  have  liver  involvement  in  the  form  of  mild 
hepatomegaly.  Modest  elevation  of  liver  enzymes  with  similar 
histological  features  of  periportal  infiltration  is  common.  Rare 
occurrence of  acute  liver  failure  is  life  threatening complication  of 
AOSD.
• Systemic lupus erythematosus (SLE)
Hepatomegaly  is  seen  in  23-39% of  patients  with  lupus.  Elevated 
transaminases  and jaundice is  seen in  24% of cases.  Cirrhosis  and 
complications  are  seen  in  2%  of  patients  whereas  abnormal  liver 
histology  is  seen  with  21% of  cases.  20% of  chronic  autoimmune 
hepatitis patients have positive criteria for SLE. (31)
• Antirheumatic drug induced liver disease
Hepatotoxicity  is  a  rare,  unpredictable,  and  dose  independent 
complication of drugs used to treat rheumatological diseases. Aspirin 
causes  elevated  transaminases  and in  high doses  can cause  Reye’s 
syndrome in children. Indomethacin and Ibuprofen are relatively safe 
with  isolated  reports  of  fatty  change  and  hepatitis.  Toxic 
granulomatous  hepatitis  is  a  life  threatening  complication  of 
Phenylbutazone occurring in 0.25% of patients.  Gold hepatitis with 
intrahepatic cholestasis has been well documented. Penicillamine and 
Azathioprine  are  known  to  cause  transaminase  elevation  and 
cholestasis.  Methotrexate  causes  hepatic  fibrosis  after  a  cumulative 
dose.
Autoimmune Hepatitis
Autoimmune  hepatitis  is  a  nonresolving  inflammation  of  the  liver  of 
unknown cause. It is characterized by the presence of interface hepatitis on 
histological  examination,  hypergammaglobulinemia,  and  autoantibodies. 
There are no features that are absolutely diagnostic, and the existence of the 
condition  can  be  established  only  by  recognition  of  a  constellation  of 
compatible features and the exclusion of other diseases. (24)
    The sine qua non of the diagnosis is the presence of interface hepatitis in 
liver  biopsy  tissue.  Plasma  cell  infiltration  strengthens  the  histological 
diagnosis, but it can occur in other forms of acute and chronic liver disease. 
The  absence  of  plasma  cell  infiltration  does  not  preclude  the  diagnosis. 
Other  histological  features  include  panacinar  (lobular)  hepatitis  and 
centrilobular necrosis. (25)
Occurrence
The incidence of autoimmune hepatitis among white northern Europeans is 
1.9 cases per 100,000 persons per year, and its point prevalence is 16.9 cases 
per 100,000 persons per year. (26)   In India incidence is said to be less than 1 
case per 100,000 persons per year. (27)  
The  disease  occurs  as  commonly  across  all  age  ranges,  and it  is  under-
diagnosed in the elderly. It is also a diagnosis that can and should be made in 
infants. Seventy-eight percent of patients are women, and the female: male 
ratio is 3.5. Women with autoimmune hepatitis have higher frequencies of 
concurrent immune diseases than men with the disease.
Symptoms and Clinical Features
Fatigue and myalgia are the most common symptoms, but 34% of patients 
are  asymptomatic  at  presentation.  These  patients  are  typically  discovered 
during routine general medical examinations that include the screening of 
liver tests. Asymptomatic patients are more commonly men, and they have 
lower serum levels of aminotransferases and globulins at presentation than 
symptomatic patients. Histological features are similar between symptomatic 
and  asymptomatic  patients,  and  there  is  no  significant  difference  in  the 
occurrence of cirrhosis. Seventy percent of asymptomatic patients become 
symptomatic, and the absence of symptoms at presentation should not deter 
treatment. (25)
       An abrupt, rarely fulminant, presentation is possible, and the diagnosis 
does not require 6 months of continuous activity to establish its chronicity 
and nature. Hepatomegaly is the most common physical finding, but 25% of 
patients will have normal physical examinations. 
     Concurrent  immune  diseases,  including  autoimmune  thyroiditis, 
ulcerative colitis, and Graves' disease, occur in 38% of patients, and celiac 
disease is important to recognize because it is typically asymptomatic, and it 
may contribute to the liver dysfunction. Immune diseases may develop at 
any time during the course of autoimmune hepatitis. (24) 
Laboratory Features
The predominant abnormalities are elevated serum aminotransferase levels, 
which can mimic  a severe acute hepatitis.  Most  patients have substantial 
increases  in  the  serum  gamma-globulin  and  immunoglobulin  G  levels. 
Strong cholestatic features,  mainly serum alkaline phosphatase levels that 
exceed 2-fold the upper limit of normal, discourage the diagnosis. Only 21% 
of  patients  have  serum  alkaline  phosphatase  levels  that  exceed  2-fold 
normal,  and none with classical  disease have serum alkaline phosphatase 
levels  that  exceed  4-fold  normal.  A  disproportionately  increased  serum 
alkaline phosphatase level points to an alternative diagnosis. (25)
Conventional Serologic Markers
Smooth  muscle  antibodies  (SMA),  antinuclear  antibodies  (ANA),  and 
antibodies  to  liver  kidney  microsome  type  1  (anti-LKM1)  constitute  the 
serologic markers for autoimmune hepatitis. None of the autoantibodies is 
pathogenic  for  the  disease  or  diagnostic  of  the  condition;  their  presence 
supports the need for further diagnostic testing. SMA and ANA are the most 
common serologic manifestations of autoimmune hepatitis,  and each may 
appear  and  disappear  in  varying titer  independently.  High titers  (titers  ≥ 
1:160) support the immune nature of the liver disease, but low titers (titers 
1:40-1:80) do not preclude the diagnosis in patients with other compatible 
features. (25)
     Liver biopsy assessment is essential to evaluate the nature of the disease 
regardless of the serologic profile. Patients with interface hepatitis who lack 
the  conventional  autoantibodies  may  have  "autoantibody-negative 
autoimmune hepatitis. These patients may be classified as having definite 
disease if repeat testing reveals SMA, ANA, or anti-LKM1, or nonstandard 
autoantibodies  such  as  perinuclear  antineutrophil  cytoplasmic  antibodies 
(pANCA) or antibodies to soluble liver antigen/liver pancreas (anti-SLA/LP) 
are detected.
Nonstandard Serologic Markers
Nonstandard  autoantibodies  are  still  being  evaluated  as  diagnostic  and 
prognostic  indices  and  have  not  been  formally  incorporated  into 
clinical algorithms. Nevertheless, they have the promise of enhancing 
diagnostic  specificity  and  adding  a  prognostic  dimension  to  the 
serologic  profile.  Perinuclear  antineutrophil  cytoplasmic  antibodies 
(pANCA)  may  be  useful  in  classifying  patients  who  lack  the 
conventional serologic markers,           and IgA antibodies to EMA 
may identify individuals with celiac-related liver disease. Antibodies 
to  SLA/LP,  actin  (antiactin),  chromatin  (antichromatin), 
asialoglycoprotein  receptor  (anti-ASGPR),  and liver  cytosol  type  1 
(anti-LC1) have been associated with severe disease or poor treatment 
response,  and  some  autoantibodies  may  be  reflective  of  genetic 
propensities that affect outcome.
    Antibodies  to  SLA/LP  and  actin  have  been  associated  with  human 
leukocyte  antigen  (HLA)  DR3,  and  there  may  be  other  serologic 
expressions  with  a  similar  genetic  association  that  augur  a  poor 
prognosis.  The  major  clinical  limitation  of  the  nonstandard 
autoantibodies has been their  low individual  occurrence in  patients 
with autoimmune hepatitis. The variable and infrequent expression of 
these antibodies in individuals with autoimmune hepatitis limits the 
value  of  any  one  determination  in  assessing  prognosis,  especially 
because the absence of the prognostic marker does not preclude a poor 
outcome
Clinical Subtypes 
Two types  of  autoimmune  hepatitis  have  been  proposed  on the  basis  of 
serologic markers. These types have not been established as valid clinical 
entities,  but  the  terms  have  been  useful  as  clinical  descriptors. 
Type1 autoimmune hepatitis is the most common form worldwide, and it 
is characterized by the presence of ANA or SMA. Eighty percent of adults 
with autoimmune hepatitis have this disease type. (32) 
      Type 2 autoimmune hepatitis is characterized by the presence of anti-
LKM1 antibodies  and  occurs  mainly  in  children  and in  Europe.  Twenty 
percent of patients with type 2 autoimmune hepatitis in Europe are adults. 
The disease subgroups have not been associated with a distinctive prognosis 
or treatment strategy. The major clinical value of this stratification has been 
to describe certain clinical phenotypes, and the major investigative value has 
been to identify homogeneous populations in which to evaluate pathogenic 
mechanisms. (28) 
Table 1.1 Subtypes of Autoimmune Hepatitis
Clinical Features Type 1 Type 2
Signature autoantibodies SMA/ ANA LKM1
Ancillary autoantibodies pANCA/ Antiactin LC1
Autoantigen Unknown CYP2D6
Age (years) Infancy to old age Pediatric (2-14)
Women (%) 78 89
Immune diseases (%) 38 34
Typical concurrent immune 
diseases
Thyroiditis
Graves' disease
Ulcerative colitis
Thyroiditis
Vitiligo
Type 1 diabetes
HLA associations B8, DR3, DR4 B14, DR3, C4A-Q0, 
DR7
Allelic risk factors DRB1*0301 
DRB1*0401
DRB1*07
Steroid responsive +++ ++
Variant syndromes (29)
Patients  with  features  of  AIH  and  another  liver  disease  (“overlap 
syndromes”) or with findings that are inconsistent with the definite diagnosis 
of  AIH  (“outlier  syndromes”)  constitute  the  variant  syndromes.  These 
variant forms have been reported extensively but the overall experience with 
these  conditions  remains  relatively  small  and  anecdotal.  Standardised 
diagnostic  criteria  have  not  been  promulgated;  experiences  between 
institutions have not been compared; natural history for each variant form 
remains  uncertain;  and  treatment  algorithms  have  not  been  validated. 
Eighteen per cent of patients with autoimmune liver disease have features 
that  vary  from the  classical  syndromes  of  AIH, primary  biliary  cirrhosis 
(PBC),  and primary  sclerosing  cholangitis  (PSC),  and  patients  with  PSC 
most  commonly  have  concurrent  features  of  AIH  that  confound  the 
diagnosis.  Recognition  of  these  variants  is  important  because  they  are 
common;  their  inclusion  in  classical  diagnostic  categories  can  distort 
perceptions  of  disease  behaviour  and  outcome;  responsiveness  to 
conventional  therapies  may  vary;  and  they  may  provide  clues  to  the 
pathogenesis of the typical disorders.
SLE and Autoimmune liver disease (46)
Although the liver is not a major target for damage in SLE, clinical  and 
biochemical  evidence  of  liver  abnormalities  are  common.  However, 
abnormality  of  liver  function  is  not  a  diagnostic  criterion  of  SLE.  After 
careful exclusion of various etiologies of liver disease, the question remains 
as to whether to classify the patient as having a primary liver disease with 
associated autoimmune features or having liver disease as a manifestation of 
SLE. Whether AIH and SLE-associated  hepatitis  are two distinct  entities 
remains unclear. Several clinical and histological features have been used to 
discriminate  AIH  from  SLE,  since  complications  and  therapy  are  very 
different in the two conditions. 
            Patients with SLE have a 25%-50% chance of developing abnormal  
liver  tests  in  their  lifetime.  The  frequency  of  liver  dysfunction  and  the 
associated portal inflammation support the view that subclinical liver disease 
is a concomitant feature of SLE. Histologically, the most common findings 
are fatty infiltration, and atrophy and necrosis of the central hepatic cells. 
                    
Approach to Diagnosis
The diagnosis of autoimmune hepatitis has been codified by an international 
panel,  and these criteria must  now be applied to all  patients suspected to 
have  the  disease.  The  definite diagnosis  requires  the  exclusion  of  other 
similar  diseases;  laboratory  findings  that  indicate  substantial  immune 
reactivity; and histologic findings of interface hepatitis. A cholestatic form 
of  autoimmune  hepatitis  is  unrecognized,  and  patients  with  pruritus, 
hyperpigmentation,  xanthelasmas,  or  disproportionately  elevated  serum 
alkaline  phosphatase  levels  must  be  evaluated  for  other  conditions.  A 
probable diagnosis  is  justified  when  findings  are  compatible  with 
autoimmune hepatitis but insufficient for a definite diagnosis. Patients who 
lack conventional autoantibodies but who are seropositive for investigational 
markers,  such  as  antibodies  to  SLA/LP,  actin,  or  LC1,  are  classified  as 
having probable disease. (34)
   DIAGNOSTIC ALGORITHM FOR AUTOIMMUNE HEPATITIS (34) 
Table 1.2 International Criteria for the Diagnosis of Autoimmune 
Hepatitis (37)
Diagnostic Criteria
Definite AIH Probable AIH
Normal alpha-1 AT phenotype
Normal ceruloplasmin level
Normal iron and ferritin levels
Partial alpha-1 AT deficiency
Nondiagnostic ceruloplasmin/copper levels
Nondiagnostic iron and/or ferritin changes
No active hepatitis A, B, and/or 
C infection
No active hepatitis A, B, and/or C 
infection
Daily alcohol < 25 g/day
No recent hepatotoxic drugs
Daily alcohol < 50 g/day
No recent hepatotoxic drugs
Predominant serum AST/ALT 
abnormality
Predominant serum AST/ALT abnormality
Globulin, gamma-globulin or 
IgG level ≥ 1.5 times upper limit 
of normal
ANA, SMA, or anti-LKM1 ≥ 
1:80 in adults and ≥ 1:20 in 
children; no AMA
Hypergammaglobulinemia of any degree
ANA, SMA or anti-LKM1 ≥ 1:40 in 
adults; other autoantibodies
Interface hepatitis, moderate to 
severe
No biliary lesions, granulomas, 
or prominent changes suggestive 
of another disease
Interface hepatitis, moderate to severe
No biliary lesions, granulomas, or 
prominent changes suggestive of another 
disease
Diagnostic scoring
A scoring system accommodates the diverse manifestations of autoimmune 
hepatitis and renders an aggregate score that reflects the net strength of the 
diagnosis before and after corticosteroid treatment. Each component of the 
syndrome  is  weighed,  discrepant  features  are  discounted,  and  biases 
associated with isolated inconsistencies are prevented. The scoring system 
was developed as a research tool to ensure comparable study populations in 
clinical trials, and it is not a discriminative diagnostic index. The sensitivity 
of the scoring system for autoimmune hepatitis ranges from 97% to 100%, 
and its  specificity  for  excluding chronic  hepatitis  C ranges  from 66% to 
92%. The major weaknesses of the scoring system have been its complexity 
and  difficulty  in  distinguishing  autoimmune  hepatitis  from  cholestatic 
syndromes  with  autoimmune  features  (accuracy,  45%  to  65%).  A 
streamlined modification of the scoring system has been developed and is 
now being promulgated. (34, 38)
Table 1.3 International Scoring System for Diagnosis of 
Autoimmune Hepatitis (34)
Sex Female +2  HLA DR3 or DR4 +1
AP:AST (or ALT) 
ratio
> 3
< 1.5
-2
+2
 Immune 
disease
Thyroiditis, colitis, 
others
+2
Gamma-globulin or 
IgG level above 
normal
> 2.0
1.5-2.0
1.0-1.5
< 1.0
+3
+2
+1
0
 Other 
markers
Anti-SLA/LP, 
actin, LC1, 
pANCA
+2
ANA, SMA, or anti-
LKM1 titers
> 1:80
1:80
1:40
< 1:40
+3
+2
+1
0
 Histologic 
features
Interface hepatitis
Plasmacytic
Rosettes
None of above
Biliary changes
Other features
+3
+1
+1
-5
-3
-3
AMA Positive -4  Treatment 
response
Complete
Relapse
+2
+3
Viral markers Positive
Negative
-3
+3
   
Drugs Yes
No
-4
+1
 Pretreatment score
Definite diagnosis: > 15
Probable diagnosis: 10-15
 
Alcohol < 25 
g/day
> 60 
g/day
+2
-2
 Posttreatment score
Definite diagnosis: > 17
Probable diagnosis: 12-17
Treatment
Corticosteroid therapy is effective in all forms of autoimmune hepatitis, and 
the combination of prednisone and azathioprine is preferred. Remission can 
be achieved in  80% of  patients  within 3 years,  and the 10-  and 20-year 
survival rates exceed 80%. Histological cirrhosis does not affect response or 
longevity, and all patients with severe disease should be treated, including 
children, elderly adults, postmenopausal women, individuals with acute or 
fulminant  presentations,  and  those  without  conventional  autoantibodies. 
Relapse  is  common,  and  long  term low-dose  prednisone  or  azathioprine 
therapy  is  preferred  after  multiple  relapses.  Sustained  remission  is 
achievable, even after relapse, in 47% within 10 years, and the long-term 
maintenance  regimens  need  not  be  indefinite.  Liver  transplantation  is 
effective,  and  its  actuarial  10-year  survival  rate  is  75%.  Drugs  such  as 
cyclosporine,  tacrolimus,  and  mycophenolate  mofetil  promise  greater 
blanket  immunosuppression,  and  site-specific  interventions  are  feasible, 
including  blocking  peptides,  soluble  cytotoxic  T  lymphocyte  antigen-4, 
cytokine manipulations, T cell vaccination, oral tolerance, and gene therapy. 
(30, 33, 36) 
Table 1.4
Conventional treatment regimen (36)
 Combination Therapy
Prednisone 
Therapy
Weeks 
Administered Prednisone (mg daily)
Azathioprine 
(mg daily)
Prednisone 
(mg daily)
1 30 50 60
1 20 50 40
2 15 50 30
Maintenance until 
endpoint
10 50 20
Optimal 
Indications Post-menopausal state
Osteoporosis or 
vertebral compression
Diabetes
Hypertension
Obesity
Emotional 
lability/depression
                               Cytopenia
                               Pregnancy
                     Active malignancy
                            Short course
                              Thiopurine 
                        methyltransferase 
                              deficiency
Table1.5
Management Options Using Evolving but Unestablished Drug 
Therapies (30)
Treatment 
Status
Evolving Drug Therapies
Naïve Cyclosporine 
(5-6 mg/kg 
daily)
Budesonide 
(3 mg twice 
daily)
Ursodeoxycholi
c acid (13-15 
mg/kg daily)
 
Treatment 
failure
6-mercapto
   purine 
(1.5 mg/kg 
daily)
Mycophenolate 
mofetil 
(2 g daily)
Cyclosporine 
(5-6 mg/kg 
daily)
Tacrolimus 
(4 mg twice 
daily)
Incomplet
e response
Budesonide 
(3 mg twice 
daily)
Ursodeoxycholi
c acid (13-15 
mg/kg daily)
 Deflazacort (7.5 
mg for every 5 
mg prednisone 
daily)
Drug 
toxicity
6-mercapto
purine (1.5 
mg/kg daily)
Cyclosporine 
(5-6 mg/kg 
daily)
Mycophenolate 
mofetil 
(2 g daily)
Ursodeoxycholi
c acid (13-15 
mg/kg daily)
Relapse Mycophenolat
e mofetil 
(2 g daily)
Deflazacort 
(7.5 mg for 
every 5 mg 
prednisone 
daily)
  
Prognosis and survival
In a large retrospective analysis of patients with AIH, all of whom received 
immunosuppressive therapy, the overall five-year survival was 85%. Those 
with  cirrhosis  had  a  significantly  worse  prognosis.  Patients  who  were 
anti-LKM antibody positive were also reported to have a poorer prognosis 
but this is probably accounted for by the high frequency of cirrhosis in this 
group. (41)
Causes of death
Other  than  incidental,  non-hepatic  causes,  death  is  now  largely  a 
consequence of cirrhosis. In the small group of steroid-resistant cases, and 
the few who present with fulminating disease, death may be due to acute 
hepatic  failure  and  its  complications—although  liver  transplantation  is 
increasingly becoming a life-saving option in these cases. For the majority, 
hepatocellular  failure  secondary  to  cirrhosis  is  the  major  cause  of  death, 
followed by variceal haemorrhage, septic complications,and hepatocellular 
carcinoma.
Autoimmune Hepatitis – Indian scenario 
There  is  considerable  geographic  variation  in  frequency  and  clinical 
manifestations  of  autoimmune  hepatitis  in  our  country.  This  is  expected 
considering  the  heterogeneity  in  genetic  makeup  and  environmental 
influences. It has been regarded as a rare cause of liver disease in India. (27) 
This may in part be due to non specific nature of symptoms and inability to 
recognize  the  disease  in  the  initial  phases.  It  is  also  due  to  the  lack  of 
awareness about the condition among general physicians and continued use 
of alternative/ herbal medicines for all patients with liver disease.
     The bottom line is that Indian data regarding the incidence, clinical, 
biochemical  and  histological  profile  of  autoimmune  hepatitis  is  scarce. 
Studies from SGPGI Lucknow and Mumbai uniformly reported an incidence 
of 1.5-2% of all liver disease. (27)   Mean age at presentation was 36 yrs with 
90% of patients being women. 50% presented with chronic hepatitis, 35% 
with  Cirrhosis  and  15%  as  acute  hepatitis.  Clinical  manifestations  were 
jaundice  (55%),  edema  and  hepatomegaly  (44%),  Splenomegaly  (35%), 
fever  (21%) and encephalopathy (24%).  Autoimmune  markers  seen were 
ASMA (57%), ANA (36%) and both (10%). Anti LKM, ANCA were not 
seen. (27)
Reasons for the study
From the above review it  is  clear  that  liver  involvement  in  autoimmune 
disease is known to occur. Autoimmune liver disease is a common cause of 
liver disease among women. It is an emerging condition in our country and 
due importance has not been given in Indian literature like that given to the 
commonly reported causes of chronic liver disease in India i.e. alcohol and 
HBV/ HCV related chronic hepatitis. The available data is scarce and mainly 
from north and west India with no studies from the south.
    Most of the studies in literature, including those from the west, tended to 
proceed from effect to cause i.e. to look at autoimmune etiology in patients 
with liver disease. This is a unique study, which addresses the problem from 
the other angle, by detecting liver involvement in autoimmune disease. This 
is important,  from the point of improving our knowledge about the early 
natural  history  of  the  condition,  and  also  provides  the  opportunity  for 
recognizing  those  at  risk  for  chronic  liver  disease  and  preventing  its 
progression.     
   
                              3  .  AIMS AND OBJECTIVES  
• To  study  the  occurrence,  clinical  presentation,  and  biochemical/ 
immunological profile of liver involvement in autoimmune diseases.
• To trace the natural history of autoimmune liver disease before the 
development of symptomatic liver disease.
• To analyse the possible etiology of liver involvement in autoimmune 
disorders.
• To formulate locally applicable protocols for diagnosis and treatment 
of autoimmune hepatitis. 
                           4. MATERIALS AND METHODS
STUDY DESIGN
        Prospective cohort study
VENUE OF THE STUDY
        Rheumatology clinic, Govt. Stanley hospital, Chennai
STUDY PERIOD
         Jan 2007 – May 2007
STUDY POPULATION
        All cases of SLE and Rheumatoid arthritis satisfying the criteria. 
INCLUSION CRITERIA
• All newly diagnosed cases of SLE and Rheumatoid arthritis by the 
American Rheumatological Association (ARA) criteria. (39, 40)
• Age > 12 yrs.
• Positive immune serological tests (RF/ ANA).
EXCLUSION CRITERIA
• Significant alcohol intake (> 40 gm/ day).
• Acute febrile illness.
• Positive viral markers (HBsAg/ anti HCV).
• Suspected or proven metabolic liver disease.
METHODS
           This study was carried out in the rheumatology clinic of GOVT. 
STANLEY HOSPITAL, Chennai. This is a tertiary referral center catering 
to  large  population  in  north  Chennai  and  neighboring  districts  of 
Thiruvallur,  Kanchipuram,  and Villupuram.  Outpatient  attendances  at  the 
clinic are about a hundred per day with an equal number of new and follow 
up cases. 
         Newly diagnosed cases of SLE and Rheumatoid arthritis were enrolled  
into  the  study.  Informed  consent  was  taken  from  all  participants.  The 
demographic profile and clinical history was recorded including complaints 
of  liver  involvement,  connective  tissue  involvement  and  associated 
endocrine  involvement.  Relevant  drug  history  was  sought  including 
alternative and herbal medicines. Detailed physical examination was done 
on  all  patients,  with  special  attention  paid  to  looking  for  features  of 
autoimmune phenomenon, like alopecia, viltigo and signs of liver disease 
like icterus, edema, hepatosplenomegaly and ascites. 
          Routine labs included complete blood count and ESR. Tests of liver 
function were recorded including prothrombin time. Immunological markers 
Rhematoid factor (RF) and anti-nuclear antibody (ANA) was done by 
immunoflourescence method.  Imaging included an ultrasound scan of the 
abdomen.  The  liver  size  and  echoes,  spleen  size,  portal  vein  diameter, 
presence of collaterals and free fluid were recorded. Upper GI endoscopy 
was  done  for  cases  when  indicated  to  look  for  evidence  of  portal 
hypertension.
         Data collected in the study proforma was organized and compiled  
using  the  Microsoft  excel  worksheet  software  version  2006.  This  was 
analysed  using  statistical  tools  to  calculate  mean,  median  and  incidence 
using internet based calculators.
                                               5. RESULTS
A total of 50 subjects satisfying the inclusion criteria were enrolled into the 
study. The mean age of  the subjects  was 35yrs,  range 12-60 yrs and the 
median age was 33 yrs. There were 40 female patients compared to 10 male 
with  male  to  female  ratio  of  1:4.  The  mean  duration  of  illness  before 
presentation to our clinic was 5 months; range 1-12 months.
AGE DISTRIBUTION
Of the 50 patients, 8 (16%) belonged to the group of ≤ 20 yrs whereas 15 
(30%) were between 21- 30 yrs. The 31- 40 yrs consisted of 9 (18%) patients 
and another 12 (24%) came in the 41-50 yrs group. The rest, i.e.       6 (12%) 
belonged to the > 50 yrs group.
Table 1.                  AGE DISTRIBUTION OF SUBJECTS                      
          AGE  (yrs)       SLE         RA      TOTAL
         <20         7          1           8
          21-30         5         10          15
          31-40         0          9           9
          41-50         1         11          12
         >50         1          5           6
SEX DISTRIBUTION
The overall  male  to  female  ratio was 1:4.  More specifically  among SLE 
patients the ratio was 1:6, whereas among Rheumatoid arthritis patients it 
was 2:7.
Table 2.       SEX DISTRIBUTION OF SUBJECTS
            SEX         SLE        RA
            Male           2         8
          Female          12        28
   
PRIMARY ILLNESS    
Of the 50 patients enrolled in the study, 14 (28%) were diagnosed to have 
SLE, whereas 36 (72%) had features of Rheumatoid arthritis. 
SYMPTOMATOLOGY AND ANALYSIS
Overall  the  frequent  presentation  was  with  non  specific  symptoms  of 
arthralgia, myalgia and loss of apetitie. Most of the patients presented as a 
chronic fatigue syndrome. Thirty patients (60%) reported to have fatigue, 44 
(88%) had arthralgia and 41 (82%) had myalgia. Jaundice, GI bleed were 
less frequent.
Table 3.              INCIDENCE OF SYMPTOMS
           Symptoms                Incidence
            Fatigue              60% (30/50)
          Anorexia              28% (14/50)
           Myalgia              82% (41/50)
         Arthralgia              88% (44/50)
          Jaundice              12% (6/50)
         GI bleed               8% (4/50)
  
Myalgia,  fatigue  and  anorexia  were  more  common  with  SLE  than 
Rheumatoid arthritis. GI bleed and jaundice occurred only in SLE patients.
Table 4.             DISTRIBUTION OF SYMPTOMS
            Symptoms           SLE           RA
               Fatigue         100%           44%
            Anorexia          92%            2%
             Myalgia          92%            78%
           Arthralgia          78%            91%
            Jaundice          43%             0%
           GI bleed          28%             0%
  
ASSOCIATED DISEASES
Diabetes was the common associated disease, seen in 30% (15/50) of cases, 
whereas thyroid disorders were seen in 18% (9/50) patients. Both were more 
frequent in Rheumatoid arthritis patients. 
Table 5.           INCIDENCE OF ASSOCIATED DISEASES
  Associated disease                SLE                 RA
          Diabetes            1/14 (7%)         14/36 (39%)    
        Thyroiditis           1/14 (7%)              8/36 (22%)
DRUGS
Two- thirds of the patients gave history of drug intake in recent past (33/50). 
NSAIDs were the commonly used seen in 23 cases (46%). A fifth (10) of the 
patients reported to using drugs of Indian systems of medicine (Ayurveda/ 
Homeopathy/ Siddha).
CLINICAL SIGNS
There was a paucity of clinical signs of liver disease like spider nevi, dilated 
veins,  flapping  tremors  etc.  Common features  were  edema,  arthritis,  and 
alopecia.  Hepatomegaly  was  seen  in  38%  (19)  of  the  cases. 
Other signs of liver disease like jaundice, Splenomegaly and ascites were 
infrequent and seen mostly in SLE patients. Three patients with SLE (21%) 
had  physical  findings  of  decompensated  chronic  liver  disease  and  portal 
hypertension. 
Table 6.  INCIDENCE AND DISTRIBUTION OF PHYSICAL SIGNS 
      PHYSICAL SIGNS         SLE           RA
                Icterus        6/14 (44%)             0
                Edema      11/14 (78%)       10/36 (27%)
               Arthritis        7/14 (50%)       31/36 (87%)
           Hepatomegaly        9/14 (64%)       10/36 (28%)
           Splenomegaly        3/14 (21%)          0
              Ascites        5/14 (36%)          0
INVESTIGATIONS
Anemia and elevated acute phase reactants like sedimentation rate   and C- 
reactive protein was frequently seen. Mean Hb was 9.6 gm% whereas mean 
ESR was 66 mm at 1 hr.  
          Modestly elevated bilirubin upto 5 mg% was seen in 6 patients (12%),
 of which 3 had decompensated liver disease. Mean albumin was 3 gm/ dL, 
and low albumin (< 2.5g %) was seen in 8 cases (16%). Mean Globulin level 
was 3.1 gm/dL; Elevated globulin (> 3.4 gm %) was seen in 21 cases (42%).
        Elevation of Liver transaminases was defined as level > 2 upper limit of 
normal  (35 iU/L) 42.  Alanine aminotransferase  (ALT) was elevated in 29 
(58%) cases. Elevation in alkaline phosphatase (ALP) was modest.
Table 7.  INCIDENCE OF LIVER ENZYME ELEVATION
       DIAGNOSIS         ALT         AST
               SLE    12/14 (86%)       9/14 (64%)
               RA    17/36 (48%)     11/36 (30%)
    
       Immunological markers, Antinuclear antibodies (ANA) was positive in 
19 (38%) cases and Rheumatoid factor (RF) in 40 (80%) patients. Both were 
positive in 5 (10%) patients.
Table 8.     INCIDENCE OF SEROLOGICAL MARKERS
        SEROLOGY   INCIDENCE
             ANA           38%
              RF           80%
ULTRASOUND FINDINGS
Hepatomegaly was most frequent finding overall. Fatty liver was seen in 9 
(18%) patients.  Three cases with decompensated liver disease had dilated 
portal vein diameter (> 1.3 cm) and Splenomegaly. Ascites was present in 8 
(16%) of scans.
Table 9.   ULTRASOUND FINDINGS
   ULTRASOUND FINDING INCIDENCE
            Hepatomegaly    12/50 (24%)
           Shrunken Liver      2/50 (4%)
               Fatty Liver      9/50 (18%)
            Coarse Echoes      3/50 (6%)
            Splenomegaly      3/50 (6%)
            Dilated Portal vein      3/50 (6%)
                 Ascites     8/50 (16%)
 
All the sonogram findings  were more  common in SLE than Rheumatoid 
arthritis. Splenomegaly, ascites and dilated portal vein were exclusively seen 
in SLE. Two cases of SLE had shrunken liver and three had coarse echoes.
Table 10.  DISTRIBUTION OF ULTRASOUND FINDINGS
ULTRASOUND FINDINGS         SLE           RA
           Hepatomegaly     9/14 (64%)       3/36 (8%)
          Shrunken Liver     2/14 (14%)             0
             Fatty Liver     4/14 (28%)       5/36 (14%)
         Coarse Echoes     3/14 (21%)             0
           Splenomegaly     3/14 (21%)             0
       Dilated Portal vein     3/14 (21%)             0
              Ascites     8/14 (57%)             0
ENDOSCOPY
Esophageal varices were seen on upper GI endoscopy in 3 patients (7%).
All  these  cases  belonged to  the SLE group and were  diagnosed to  have 
decompensated chronic liver disease with portal hypertension. One patient in 
the  SLE group underwent  colonoscopy  for  hematochezia  which  revealed 
findings consistent with Ulcerative colitis.
            
                            6. DISCUSSION 
The findings of this study corroborate well with national and international 
literature but at the same time highlight some interesting points of difference 
between the two. This may be attributed to the genetic, geographical and 
racial  differences  between  our  population  and  the  west.  Because  of  the 
unique  perspective  of  this  study,  we  are  able  to  look  at  the  problem of 
autoimmune liver  disease at its  early stage.  It  provides an opportunity to 
appreciate  the natural  history  and wide variety  of  liver  manifestations  in 
autoimmune diseases.
           A similar account was published by Angela Hilton and others  (21), 
from  Univ.  Hospital  of  South  Manchester,  in  the  Annals  of  rheumatic 
Diseases.  This particular study looked at liver abnormalities patients with 
joint  symptoms  of  varied  etiology.  Thirty  patients  suffering  from  SLE, 
Rheumatoid arthritis, Gout and other disorders were evaluated with routine 
liver function tests, immunology and histology. They did not exclude any 
patients with alcoholic or viral hepatitis. 
        The commonest abnormality was elevated transaminase (ALT); seen in 
19 patients  (63%),  low serum albumin  in  6  patients  (20%) and  elevated 
serum globulin in 16 cases (53%). This is comparable to the results of our 
study, where 29 patients (58%) had elevated ALT, 8 (16%) had low albumin 
and 21 patients (42%) had elevated serum globulins. The Manchester study 
concluded that detailed hepatic investigations are justified in patients with 
rheumatic diseases, who have hepatomegaly and/or abnormal LFT. Further, 
it  should  not  be  assumed  that  these  abnormalities  are  due  to  liver 
involvement  as  part  of  a  multisystem autoimmune  disease.  Specific  liver 
disease must be looked for and treated accordingly when indicated.
             Similar results were reported in the study done by Cockel R and 
Kendall  M J  (42) which  was  also  published  in  the  Annals  of  Rheumatic 
Diseases.
            An interesting study was done was Koichi Kushimoto and colleagues 
from Kyushu University in Japan (43). They looked at liver abnormalities in 
57 patients with SLE. Elevated transaminases were seen in 56% of cases. Of 
great interest to us is the finding that three of their patients had fatty liver 
compared to the four of our SLE patients who also had fatty liver. This gives 
the  impression  that  autoimmune  liver  disease  probably  passes  through  a 
phase  of  fatty  liver,  similar  to  that  seen  in  alcoholics,  before  causing 
Cirrhosis.  The  importance  of  this  finding  lies  in  the  fact  that  these 
individuals can be identified as to being at  high risk for  development  of 
Cirrhosis, hence requiring aggressive therapy and surveillance.  
Rothfield (43) and Morito (44) observed similar abnormalities in SLE patients.
Dubois and Tuffanelli (45) found jaundice in only 3.8% of 520 cases of SLE. Koffman (46) 
in  a  study reported  jaundice  in  12% of  SLE patients.  This  is  concurrent  to  the  low 
incidence of jaundice (6 cases/ 12%) in our study.
        Choudhuri et al published a series of 41 cases of autoimmune liver disease  (27).This 
formed 1.7% of all liver disease seen at SGPGIMS Lucknow between 1999 and 2002. 
The presentations were Jaundice in 21 (55%), fatigue, edema and hepatomegaly in 17 
cases (44%), Splenomegaly in 13 cases (34%). Diabetes and thyroiditis were the most 
common associated extra hepatic diseases. High ESR was seen in 55%, elevated ALT in 
75%, and high globulin in 58% of cases. In our study edema was seen in 42%, fatigue in 
60% and hepatomegaly in 38% of cases. Lower incidence of Splenomegaly (6%) and 
jaundice (12%) can be attributed to seeing the patients at an earlier  stage before they 
develop serious liver disease.
       There are some shortcomings of our study; mostly due to lack of facilities in the 
Govt. setup. The obvious one is that liver biopsy was not done for finding the cause for 
liver dysfunction in these patients. This was technically not feasible in this institution. 
The other drawback is the non availability of some autoimmune markers like anti smooth 
muscle antibody (ASMA), anti actin antibody and pANCA titres. A valid criticism was 
that the design did not include any control population.  This was because of the pilot 
nature of the study and future studies can improve on study design by including larger 
sample and adequate controls. A hospital based study like this suffers from a referral bias, 
but this  is  unavoidable  and in any case large population studies for rare  diseases are 
neither feasible nor necessary. 
                                           7. CONCLUSION
• Liver dysfunction is common in autoimmune diseases like SLE and 
Rheumatoid arthritis.
• There is a female predominance; majority of cases are young women.
• Presentations are commonly non specific with myalgia, arthralgia and 
chronic fatigue syndrome. Symptoms of liver disease are uncommon. 
• Diabetes and thyroid disorders are commonly associated disorders.
• Drugs  like  Nsaids  and  native  medicines  may  contribute  to  liver 
dysfunction in some patients, the nature of which needs to be studied.
• Hepatomegaly and edema are frequent early physical findings; signs 
of liver disease like Splenomegaly and ascites appear late.
•  Transaminase elevation are early and sometimes the only sign of liver 
involvement. Low albumin and high globulin may be seen in patients.
• Serological markers of autoimmunity are positive in most of the cases. 
Presence of multiple markers is probably proportional to activity.
• Fatty liver is seen in few cases which may predict the appearance of 
progressive liver disease at a later stage.
• A small minority of patients present with decompensated liver disease 
and signs of portal hypertension, with varices and ascites.
       This study was undertaken to get an idea about the early natural history 
of liver involvement in autoimmune disease. The findings suggest that liver 
involvement is quite common in autoimmune disease. Initially it may be non 
specific  with  elevation  of  transaminases  as  the  sole  presentation.  Long 
standing illness may present as decompensated chronic liver disease. It is 
probable that fatty infiltration of liver may be the missing link of this natural 
history. Findings which support this are the frequent occurrence of fatty liver 
in autoimmune diseases like SLE, and also in Hepatitis C related chronic 
hepatitis which is associated with autoimmune features.  
         This study also emphasizes a couple of points in the diagnostic aspects 
of autoimmune liver disease. One is the need for liver biopsy to confirm the 
diagnosis  of  autoimmune  liver  disease.  Unfortunately  in  developing 
countries this facility is not available at all centers. Secondly, we need to 
draw our own algorithms and protocols  for  diagnosing autoimmune liver 
disease. An ideal protocol will be one which doesn’t require a biopsy for 
diagnosing and starting treatment. 
     Hence this study provides the platform for further controlled studies 
with larger sample size using more serological markers. This will help in 
arriving at our own protocols for diagnosis and treatment.
                      KEY TO MASTER CHART 
• SLE – Systemic Lupus erythematosus
• RA – Rheumatoid arthritis
• F – Female
• M – Male 
• P – Present
• A – Absent
• E – Enlarged
• N – Normal
• S – Shrunken
• C – Coarse
• F – Fatty
• V – Varices 
• D – Dilated 
• IBD – Inflammatory bowel disease
• T. Bili – Total bilirubin
• AST – Aspartate aminotransferase
• ALT – Alanine aminotransferase
• ALP – Alkaline phosphatase 
                             STUDY PROFORMA
Demographic profile
Name:                                                             Age/ sex: 
Address:                                                          Ref no:
Diagnosis
Clinical information                                                             
  Fatigue:                    Anorexia:                         Myalgia:  
Jaundice:                  GI bleed:                        Thyroid:                     IBD: 
Medications:                  
Examination 
Oral ulcers:                  Icterus:                      Edema:                       Vitiligo:  
Goiter:                         Arthritis:                    Rash:                        Alopecia:  
Spider nevi:                 Cushing’s:                Dilated veins:    Hepatomegaly:  
Splenomegaly:            Ascites:
Liver function tests
T. Bili              D. Bili               T. Prot          Alb            Glob  
A:G =              AST:            ALT:           SAP:            Pro time:
Hemogram
Hb:            TC:                DC:                ESR:  
Serology
ANA:                              RA factor:
Viral markers
HBsAg:                           Anti HCV:
Ultrasound
Liver size:                      Echotexture:                       Spleen: 
Portal vein:                                   Free fluid:      
Endoscopy                                   
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